Behavioral counseling and abstinence‐contingent take‐home buprenorphine in general practitioners’ offices in Malaysia: a randomized, open‐label clinical trial

Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others

(2020) Mark Olfson et al.   HEALTH AFFAIRS

Comparing Buprenorphine-Prescribing Physicians Across Nonmetropolitan and Metropolitan Areas in the United States

(2019) Lewei (Allison) Lin et al.   ANNALS OF FAMILY MEDICINE

Management of opioid use disorders: a national clinical practice guideline

(2018) Julie Bruneau et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The Next Stage of Buprenorphine Care for Opioid Use Disorder

(2018) Stephen A. Martin et al.   ANNALS OF INTERNAL MEDICINE

Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus

(2017) Maurice Dematteis et al.   EXPERT OPINION ON PHARMACOTHERAPY

Primary care models for treating opioid use disorders: What actually works? A systematic review

(2017) Pooja Lagisetty et al.   PLoS One

Primary Care–Based Models for the Treatment of Opioid Use Disorder

(2016) P. Todd Korthuis et al.   ANNALS OF INTERNAL MEDICINE

A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction

(2016) Karen Dugosh et al.   Journal of Addiction Medicine

Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013

(2016) Louisa Degenhardt et al.   LANCET INFECTIOUS DISEASES

Buprenorphine/naloxone treatment practices in Malaysia: Results of national surveys of physicians and patients

(2015) B. Vicknasingam et al.   DRUG AND ALCOHOL DEPENDENCE

Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program

(2015) Adam J. Gordon et al.   Journal of Addiction Medicine

Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine–naloxone and standard medical management?

(2014) Roger D. Weiss et al.   DRUG AND ALCOHOL DEPENDENCE

Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes

(2013) Marwan S. Haddad et al.   DRUG AND ALCOHOL DEPENDENCE

Substance abuse and the HIV situation in Malaysia

(2013) Darshan Singh et al.   JOURNAL OF FOOD AND DRUG ANALYSIS

Contingency management in substance abuse treatment: A structured review of the evidence for its transportability

(2011) Bryan Hartzler et al.   DRUG AND ALCOHOL DEPENDENCE

Contingency management treatments: controversies and challenges

(2010) NANCY M. PETRY   ADDICTION

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers

(2010) Sandra D. Comer et al.   ADDICTION

Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: A pilot randomized clinical trial

(2010) M.C. Chawarski et al.   DRUG AND ALCOHOL DEPENDENCE

Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: A pilot randomized clinical trial

(2008) M.C. Chawarski et al.   DRUG AND ALCOHOL DEPENDENCE

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

(2008) Richard S Schottenfeld et al.   LANCET